- Home
- WHG vs TLSI Comparison
WHG vs TLSI Comparison
Compare WHG & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHG
- TLSI
- Stock Information
- Founded
- WHG 1983
- TLSI 2010
- Country
- WHG United States
- TLSI United States
- Employees
- WHG N/A
- TLSI N/A
- Industry
- WHG Investment Managers
- TLSI Medical Specialities
- Sector
- WHG Finance
- TLSI Health Care
- Exchange
- WHG Nasdaq
- TLSI Nasdaq
- Market Cap
- WHG 147.1M
- TLSI 160.4M
- IPO Year
- WHG 2002
- TLSI N/A
- Fundamental
- Price
- WHG $16.47
- TLSI $5.52
- Analyst Decision
- WHG
- TLSI Strong Buy
- Analyst Count
- WHG 0
- TLSI 6
- Target Price
- WHG N/A
- TLSI $11.75
- AVG Volume (30 Days)
- WHG 18.8K
- TLSI 67.6K
- Earning Date
- WHG 04-30-2025
- TLSI 03-27-2025
- Dividend Yield
- WHG 3.66%
- TLSI N/A
- EPS Growth
- WHG N/A
- TLSI N/A
- EPS
- WHG 0.26
- TLSI N/A
- Revenue
- WHG $94,721,000.00
- TLSI $29,431,000.00
- Revenue This Year
- WHG N/A
- TLSI $55.43
- Revenue Next Year
- WHG N/A
- TLSI $50.09
- P/E Ratio
- WHG $64.58
- TLSI N/A
- Revenue Growth
- WHG 5.50
- TLSI 58.99
- 52 Week Low
- WHG $11.01
- TLSI $3.50
- 52 Week High
- WHG $18.03
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- WHG 57.64
- TLSI 52.49
- Support Level
- WHG $15.03
- TLSI $5.23
- Resistance Level
- WHG $17.25
- TLSI $5.72
- Average True Range (ATR)
- WHG 0.64
- TLSI 0.35
- MACD
- WHG 0.11
- TLSI 0.02
- Stochastic Oscillator
- WHG 65.85
- TLSI 78.72
About WHG Westwood Holdings Group Inc
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals, and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high-net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.